GALMED PHARMACEUTICALS LTD's ticker is GLMD and the CUSIP is M47238106. A total of 39 filers reported holding GALMED PHARMACEUTICALS LTD in Q3 2018. The put-call ratio across all filers is 34.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $56 | -25.3% | 131,628 | -11.8% | 0.00% | – |
| Q4 2022 | $75 | -99.5% | 149,217 | +218.4% | 0.00% | – |
| Q3 2022 | $15,000 | -57.1% | 46,866 | -7.6% | 0.00% | – |
| Q2 2022 | $35,000 | +105.9% | 50,748 | +372.3% | 0.00% | – |
| Q1 2022 | $17,000 | -82.5% | 10,745 | -79.8% | 0.00% | – |
| Q4 2021 | $97,000 | +169.4% | 53,239 | +308.4% | 0.00% | – |
| Q3 2021 | $36,000 | -56.1% | 13,036 | -44.9% | 0.00% | – |
| Q1 2020 | $82,000 | -5.7% | 23,658 | +57.7% | 0.00% | – |
| Q4 2019 | $87,000 | -38.3% | 15,000 | -27.6% | 0.00% | – |
| Q4 2018 | $141,000 | -96.9% | 20,706 | -93.7% | 0.00% | -100.0% |
| Q3 2018 | $4,483,000 | +19.5% | 330,103 | +4.7% | 0.01% | 0.0% |
| Q2 2018 | $3,753,000 | +3892.6% | 315,356 | +1768.2% | 0.01% | – |
| Q1 2018 | $94,000 | – | 16,880 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 1,878,508 | $12,830,000 | 1.68% |
| Knoll Capital Management, LLC | 210,000 | $1,434,000 | 1.63% |
| Vivo Capital, LLC | 971,337 | $6,634,000 | 0.85% |
| P.A.W. CAPITAL CORP | 90,000 | $615,000 | 0.77% |
| 683 Capital Management, LLC | 1,350,000 | $9,221,000 | 0.56% |
| Ibex Investors LLC | 500,000 | $3,415,000 | 0.56% |
| MEITAV INVESTMENT HOUSE LTD | 653,667 | $4,465,000 | 0.28% |
| FIRST MIDWEST BANK TRUST DIVISION | 214,872 | $1,468,000 | 0.22% |
| Nantahala Capital Management | 834,401 | $5,699,000 | 0.18% |
| PREMIER ASSET MANAGEMENT LLC | 73,950 | $505,000 | 0.14% |